Laboratorios Farmaceuticos Rovi S.A.

ROVI is a pharmaceutical company that researches, develops, manufactures, and markets pharmaceutics. Founded in 1946, the company has its headquarters in Madrid, Spain. It operates in 65 countries worldwide and markets Enoxaparin, one of its anticoagulant products, directly in seven of these countries. Apart from marketing licensed products, ROVI also provides manufacturing, filling, and packaging services to other companies. Its functions are divided across three divisions; Pharmaceutical Products, Contract Manufacturing, and Research and Development. ROVI’s listed name on the Soc.Bol SIBE is Laboratorios Farmaceuticos Rovi, S.A., and it trades under the ticker ROVI. As of 2019, the company invested €29.3m in research and development. In its November 2020 investor’s presentation, ROVI announced intentions to establish a specialised sales team marketing psychoactive medicines and to negotiate a partnership with Moderna. These movements will affect ROVI stock, and as of December 2020, the company is valued at more than €1.8bn. The company’s main products include anticoagulants, cardiovascular therapeutics, hypercholesterolemia treatments, and bronchodilators. In November 2020, phase III clinical trials for the antipsychotic drug Doria® delivered desirable results. This drug is a once-monthly dose of antipsychotic medication to be administered to patients with schizophrenia. The completed clinical testing results reflected efficacy. Track the ROVI share price by adding it to your eToro watchlist.